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Abstract
Hsp90 is a molecular chaperone with important roles in regulating pathogenic transformation. In addition to its well-
characterized functions in malignancy, recent evidence from several laboratories suggests a role for Hsp90 in 
maintaining the functional stability of neuronal proteins of aberrant capacity, whether mutated or over-activated, 
allowing and sustaining the accumulation of toxic aggregates. In addition, Hsp90 regulates the activity of the 
transcription factor heat shock factor-1 (HSF-1), the master regulator of the heat shock response, mechanism that cells 
use for protection when exposed to conditions of stress. These biological functions therefore propose Hsp90 inhibition 
as a dual therapeutic modality in neurodegenerative diseases. First, by suppressing aberrant neuronal activity, Hsp90 
inhibitors may ameliorate protein aggregation and its associated toxicity. Second, by activation of HSF-1 and the 
subsequent induction of heat shock proteins, such as Hsp70, Hsp90 inhibitors may redirect neuronal aggregate 
formation, and protect against protein toxicity. This mini-review will summarize our current knowledge on Hsp90 in 
neurodegeneration and will focus on the potential beneficial application of Hsp90 inhibitors in neurodegenerative 
diseases.
Roles of Hsp90 in neurodegeneration
Hsp90 is a molecular chaperone with important roles in
maintaining the functional stability and viability of cells
under a transforming pressure [1-3]. For neurodegenera-
tive disorders associated with protein aggregation, the
rationale has been that inhibition of Hsp90 activates heat
shock factor-1 (HSF-1) to induce production of Hsp70
and Hsp40, as well as of other chaperones, which in turn,
promote disaggregation and protein degradation [4-6].
However, recent evidence reveals an additional role for
Hsp90 in neurodegeneration. Namely, Hsp90 maintains
the functional stability of neuronal proteins of aberrant
capacity, thus, allowing and sustaining the accumulation
of toxic aggregates [7,8]. Below, we summarize the cur-
rent understanding on these Hsp90 biological roles and
review potential applications of pharmacological Hsp90
inhibition in neurodegenerative diseases.
1. HSF-1 is a master regulator of the heat shock response
Exposed to conditions of stress, cells normally respond by
activation of the heat shock response (HSR) accompanied
by increased synthesis of a number of cytoprotective heat
shock proteins (Hsps) which dampen cytotoxicity, such as
caused by misfolded and denatured proteins [4-6]. The
most prominent part of this transition occurs on the tran-
scriptional level. In mammals, protein-damaging stress is
regulated by activation of HSF-1, which binds to
upstream regulatory sequences in the promoters of heat
shock genes [9]. The activation of HSF-1 proceeds
through a multi-step pathway, involving a monomer-to-
trimer transition, nuclear accumulation and extensive
posttranslational modifications (Fig. (1A)). The function
of HSF-1 is regulated by Hsp90 [10]. Namely, under non-
stressed conditions, Hsp90 binds to HSF-1 and maintains
the transcription factor in a monomeric state. Stress, heat
shock or inhibition of Hsp90 release HSF-1 from the
Hsp90 complex, which results in its trimerization (Fig.
(1B)), activation and translocation to the nucleus where it
initiates a heat shock response, manifested in the produc-
tion of Hsps such as the chaperones Hsp70 and its activa-
tor, Hsp40 (Fig. (1A,C)). Neurons in the differentiated
state, both in vivo and  in vitro systems have been
reported to be resistant to Hsp induction following con-
ventional heat shock [5]. In contrast, pharmacologic
induction of Hsp70 upon HSF-1 activation has been doc-
umented, and moreover as described below, demon-
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strated to be protective in neurons against toxicity caused
by multiple types of insults.
1.1. Hsp70 redirects neuronal aggregate formation and 
protects against aggregate toxicity
Frequently, neurodegenerative diseases are characterized
by a gain of toxic function of misfolded proteins. Here,
toxicity may result from an imbalance between normal
chaperone capacity and production of dangerous protein
species. Increased chaperone expression can suppress the
neurotoxicity of these molecules, suggesting possible
therapeutic strategies. Indeed, several studies summa-
rized below, have reported a reduction in cellular toxicity
upon expression of Hsp70 and Hsp40 in neurodegenera-
tive aggregation disease models.
The polyglutamine (polyQ) diseases consist of nine
neurodegenerative diseases in which a polyQ tract expan-
sion leads to protein misfolding and subsequent deposi-
tion of protein aggregates in neurons [11]. Among these
are Huntington's disease (HD), spinal and bulbar muscu-
lar atrophy (SBMA), Dentatorubral-pallidoluysian atro-
phy (DRPLA), and several ataxias (SCA1-3). In HD,
mutant forms of huntingtin (htt) with expanded glu-
tamine repeats form nuclear and cytoplasmic aggregates.
Muchowski et al found that Hsp70 and its cochaperone
Hsp40 suppressed the assembly of htt into spherical and
annular polyglutamine oligomers and thus attenuated the
formation of detergent-insoluble amyloid-like fibrils [12].
Likewise, in a yeast model of HD, expression of Hsp70
and Hsp40 reduced the toxicity associated with expres-
sion of mutant htt by preventing its aberrant interaction
with an essential polyQ-containing transcription factor
[13]. Studies in a mouse model of HD suggested that in
neurons, protection by Hsp70 against the toxic effects of
misfolded htt protein occurred by mechanisms indepen-
dent of the deposition of fibrillar aggregates, namely by
binding monomeric and/or low molecular mass SDS-sol-
Figure 1 Heat shock proteins are induced upon Hsp90 inhibition. (A) Schematic representation of HSF-1 regulation by Hsp90 and its activation 
by Hsp90 inhibitors. (B) Treatment of cells with heat shock or an Hsp90 inhibitor (Hsp90i) results in HSF-1 trimerization [10]. (C) Systemic administration 
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uble oligomers that are likely off-pathway to fibril forma-
tion, but may be potentially pathogenic [14]. In a
mammalian model of spinocerebellar ataxia (SCA) type 1,
expression of Hsp70 afforded protection against polyQ-
induced neurodegeneration [15]. Pharmacological induc-
tion of heat-shock proteins in spinal and bulbar muscular
atrophy (SBMA)-transgenic mice suppressed nuclear
accumulation of the pathogenic androgen receptor (AR)
protein, resulting in amelioration of polyglutamine-
dependent neuromuscular phenotypes [16].
In amyotrophic lateral sclerosis (ALS), the FDA-
approved drug riluzole was reported to partly act by HSF-
1 activation and amplification of the HSR [17]. In the
Superoxide dismutase 1 (SOD1) mouse model of ALS,
elevation in levels of Hsp70 by another agent, arimoclo-
mol, protected motor-neurons in both acute injury-
induced motor-neuron degeneration as well as progres-
sive motor-neuron degeneration models [18].
In various cellular models of Alzheimer's disease (AD),
increased levels of Hsp70 promoted tau solubility and tau
binding to microtubules [19]. Hsp70 also inhibited the
propensity of Aβ to aggregate [20], and reduced the toxic-
ity of Aβ on neuronal cultures [21]. Moreover, Amyloid
precursor protein (APP) and/or its amyloidogenic deriva-
tive Aβ are targets of chaperone mediated clearance
[22,23]. In Drosophila melanogaster and yeast models of
Parkinson's disease (PD), directed expression of Hsp70 or
pharmacologic Hsp modulation prevented the neuronal
loss caused by α-synuclein [24,25]. Huang et al reported
that these effects of Hsp70 manifested by inhibition of α-
synuclein fibril formation via preventing the formation of
prefibrillar α-synuclein formation [26]. Using α-synuclein
deletion mutants, Luk et al indicated that interactions
between the Hsp70 substrate binding domain and the α-
synuclein core hydrophobic region mediated assembly
inhibition, and that the assembly process was inhibited
prior to the elongation stage [27].
Overall, in the several neurodegenerative disease mod-
els presented above, overexpression of Hsp70 improved
the severities of several disease phenotypes without visi-
bly affecting aggregate formation, suggesting that chaper-
ones do not prevent aggregation per se, but rather
redirect aggregates into amorphous deposits, thereby
sequestering potentially toxic species from bulk solution.
1.2. Expression of Hsp70 and other Hsps are induced upon 
pharmacologic Hsp90 inhibition
As noted above, inhibition of Hsp90 releases HSF-1 from
the Hsp90 complex resulting in subsequent production of
Hsps (Fig. (1)), and induction of Hsp70 by Hsp90 inhibi-
tors is well documented in neurodegenerative disease
models. Geldanamycin (GM) (Fig. (2)), an Hsp90 inhibi-
tor [28], induced a dose-dependent increase of Hsp70 in
an AD cell model, as well as in rat primary cortical neu-
rons [19] and reduced the amount of insoluble tau and
the basal levels of okadaic-acid induced tau phosphoryla-
tion [19]. Treatment of primary cortical neurons with the
purine-scaffold Hsp90 inhibitor PU24FCl, led to a dose-
dependent increase in Hsp70 [29]. Similarly, administra-
tion of two CNS-permeable PU24FCl-derivatives, PU-
DZ8 (Fig. (2)) [29] and EC102 [30], to tau transgenic mice
(htau and JNPL3) resulted in Hsp70 induction in the
brain, effects maintained at 24 h post-administration.
KU32, an Hsp90 inhibitor of distinct chemical nature
(Fig. (2)), induced Hsp70 in SH-SY5Y neuroblastoma cul-
tures and protected them against Aβ-induced toxicity
[31]. GM activated a heat shock response and inhibited
htt aggregation in a cell culture model of HD [32,33] and
induced Hsp70 in a time- and concentration-dependent
manner and prevented α-synuclein aggregation and pro-
tected against toxicity in a cellular α-synuclein aggrega-
tion model [34]. Auluck et al reported that treatment of a
fly model of PD with GM fully protected against α-synu-
clein toxicity [35]. GM also protected against 1-methyl-4-
pheny-1,2,3,6-tetrahydropyridine (MPTP)-induced dop-
aminergic neurotoxicity, a mouse model of PD [36]. Pre-
treatment with GM via intracerebral ventricular
injection, prior to MPTP treatment, induced Hsp70 and
increased residual dopamine content and tyrosine
hydroxylase immunoreactivity in the striatum [36].
Hsp70 induction in the spinal cord was noted upon intra-
peritoneal injection of a GM derivative, 17-AAG, in a
mouse model of SBMA [37]. 17-AAG was also effective
against neurodegeneration in other polyQ diseases [38].
Namely, it suppressed compound eye degeneration and
inclusion body formation and rescued the lethality in a
Drosophila model of SCA. It also suppressed neurode-
generation in a HD fly model. Knockdown of HSF-1 abol-
Figure 2 Chemical structures of several representative Hsp90 in-
hibitors. GM = ansamycin class; PU-DZ8 = purine-scaffold class; KU-32 
= novobiocin class.Luo et al. Molecular Neurodegeneration 2010, 5:24
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ished the induction of molecular chaperones and the
therapeutic effect of 17-AAG on polyQ-induced neuro-
degeneration in the Drosophila models, arguing that the
therapeutic effect of 17-AAG was mainly HSF1-mediated
[38].
In summary, HSF-1 activation by Hsp90 inhibitors was
noted in several in vitro and in vivo models of neurode-
generative disease, suggesting Hsp90 inhibition as a
means to modulate Hsp levels in the diseased brain, with
the goal of protecting against the toxic proteins that arise
during the neurodegenerative process.
2. Inhibition of Hsp90 reduces aberrant neuronal protein 
activity and expression
In addition to regulation of HSF-1, recent evidence sug-
gests an additional role for Hsp90 in maintaining the
functional stability of neuronal proteins of aberrant
capacity (Fig. (3A)).
SBMA is an inherited motor neuron disease caused by
the expansion of a polyglutamine tract within the andro-
gen receptor (AR) [11]. The pathologic features of SBMA
are motor neuron loss in the spinal cord and brainstem
and diffuse nuclear accumulation and nuclear inclusions
of the mutant AR (mAR) in the residual motor neurons
and certain visceral organs. Waza et al demonstrated that
mAR present in SBMA is one of the proteins regulated by
Hsp90 (Fig. (3A)) [37]. Hsp90 formed a molecular com-
plex with mAR to maintain its functional stability. In both
SBMA cell models and transgenic mice, inhibition of
Hsp90 by 17-AAG led to a preferential degradation of the
mAR, mainly by the proteasome machinery. These effects
of 17-AAG were uncoupled from induction of Hsp70, and
resulted from direct destabilization of mAR and its sub-
sequent degradation upon Hsp90 inhibition. In a trans-
genic mouse model of SBMA, 17-AAG ameliorated
motor impairments without detectable toxicity, and
reduced the amounts of monomeric and aggregated mAR
[37]. Similar findings were reported by Thomas et al;
these authors found that pharmacologic Hsp90 inhibition
blocked the development of aggregates of the expanded
glutamine androgen receptor (AR112Q) in HSF1(-/-)
mouse embryonic fibroblasts where Hsp70 and Hsp40
chaperones were not induced [39].
Parkinson disease (PD), the most common neurode-
generative movement disorder, is characterized by a com-
plexity of pathogenic events [40], many of which were
recently linked to Hsp90 (Fig. (3A)). Wang et al have
r e c e n t l y  s h o w n  t h a t  L e u c i n e - r i c h  r e p e a t  k i n a s e  2
(LRRK2), a kinase of whose mutated forms is prevalent in
both familial and apparently sporadic cases of PD, formed
a complex with Hsp90 in vivo [41]. Inhibition of Hsp90
function by the purine-scaffold Hsp90 inhibitor PU-H71
disrupted the association of Hsp90 with LRRK2 and led
to elimination of LRRK2 by the proteasome. PU-H71 lim-
ited the mutant LRRK2-elicited toxicity to neurons and
rescued the axon growth retardation defect caused by the
LRRK2 G2019S mutation in neurons [41]. Mutation of
PTEN-induced kinase 1 (PINK1), which encodes a puta-
tive mitochondrial serine/threonine kinase, leads to
PARK6, an autosomal recessive form of familial Parkin-
son's disease [40]. The recessive inheritance of this form
of Parkinson's disease suggests loss of PINK1 function is
closely associated with its pathogenesis. Moriwaki et al
have reported that Hsp90 binds PINK1 to enhance its sta-
bility. In cells treated with the Hsp90 inhibitor GM, levels
of PINK1 were greatly diminished via the ubiquitin-pro-
teasome pathway [42]. α-Synuclein is an intrinsically
unstructured protein that may form fibrils, and is also
involved in PD neurodegeneration [40]. Falsone et al has
recently reported that Hsp90 influences α-synuclein vesi-
cle binding and amyloid fibril formation, two processes
that are tightly coupled to α-synuclein folding [43].
Namely, Hsp90 bound α-synuclein and abolished the
interaction of this polypeptide with small unilamellar ves-
icles. Hsp90 also promoted fibril formation in an ATP-
dependent manner via oligomeric intermediates [43].
Another link between α-synuclein and Hsp90 was pro-
vided by Kabuta et al [44]. Alpha-synuclein is degraded at
least partly by chaperone-mediated autophagy (CMA).
The authors suggested that aberrant interaction of
mutant ubiquitin C-terminal hydrolase L1 (UCH-L1)
with the chaperone-mediated autophagy CMA machin-
ery, at least partly accounted for the pathogenesis of PD
associated with I93M UCH-L1 and the increase in the
amount of α-synuclein [44].
In tauopathies, neurodegenerative diseases character-
ized by tau protein abnormalities, transformation is char-
acterized by abnormalities in the tau protein leading to an
accumulation of hyperphosphorylated and aggregated
tau [45]. In AD, tau hyperphosphorylation is suggested to
be a pathogenic process caused by aberrant activation of
several kinases, in particular cyclin-dependent protein
kinase 5 (CDK5) and glycogen synthase kinase-3 beta
(GSK3β), leading to phosphorylation of tau on patho-
genic sites [46]. Hyperphosphorylated tau in AD is
believed to misfold, undergo net dissociation from micro-
tubules and form toxic tau aggregates. In a cluster of
tauopathies termed "frontotemporal dementia and par-
kinsonism linked to chromosome 17 (FTDP-17)", trans-
formation is caused by several mutations in human tau
isoforms on chromosome 17, that result in and are char-
acterized by the accumulation of aggregated tau similar
to that in AD [47]. Luo et al have reported that the stabil-
ity of p35 and p25, neuronal proteins that activate CDK5
through complex formation leading to aberrant tau phos-
phorylation, and that of mutant but not wild type tau pro-
tein, were maintained in tauopathies by Hsp90 (Fig. (3A))
[29]. Inhibition of Hsp90 in both cellular and mouseLuo et al. Molecular Neurodegeneration 2010, 5:24
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Figure 3 Hsp90 shelters aberrant neuronal proteins. (A) Aberrant neuronal proteins regulated by Hsp90. To tolerate the accumulation of dysreg-
ulated processes and to allow the development of the disease phenotype, the functional stability of these aberrant processes likely requires a "buff-
ering" mechanism, such as offered by Hsp90. These aberrant neuronal proteins activities develop Hsp90-dependency and promote disease 
progression. (B) Pharmacologic Hsp90 inhibition results in inactivation or degradation of Hsp90-regulated proteins, mainly by a proteasomal pathway.
A
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models of tauopathies led to reduction of the pathogenic
activity of these proteins and resulted in a dose- and
time-dependent elimination of aggregated tau [29].
When administered 5xweek for 30 days to JNPL3 trans-
genic (tg) mice, PU-DZ8 (Fig. (2), led to significant reduc-
tion in mutant tau expression and phosphorylation
without toxicity to the mice [29]. Complementarily,
Dickey et al demonstrated that the EC102 Hsp90 inhibi-
tor promoted selective decrease in ptau species in a tg
mouse model of AD independent of HSF-1 activation
(Fig. (3A)) [30]. Both reports identify the proteasomal
pathway as responsible for degradation of the aberrant
tau species following Hsp90 inhibition [29,30]. A link
between Hsp90 and GSK3β was reported by Dou et al
(Fig. (3A)) [48]. Namely, the stability and function of the
GSK3β was found to be maintained by Hsp90, and Hsp90
inhibition by GM and PU24FCl led to a reduction in the
protein level of GSK3β, effect associated with a decrease
in tau phosphorylation at putative GSK3β sites [48]. Fur-
ther, Tortosa et al reported that binding of Hsp90 to tau
facilitates a conformational change in tau that could
result in its phosphorylation by GSK3 and its aggregation
into filamentous structures [49].
Collectively, the above data suggest that at the pheno-
typic level, Hsp90 appears to serve as a biochemical buf-
fer for the numerous aberrant processes that facilitate the
evolution of the neurodegenerative phenotype (Fig. (3A)).
Inhibition of Hsp90 by small molecules results in the
destabilization of the Hsp90/aberrant protein complexes
leading primarily to degradation of these proteins by a
proteasome-mediated pathway (Fig. (3B)).
Conclusion
Collectively, these reports suggest that in neurodegenera-
tive diseases Hsp90 inhibition may offers a dual therapeu-
tic approach. On one hand, its benefits may come from
induction of Hsp70 and other chaperones able of redi-
recting neuronal aggregate formation, and capable of pro-
tective potential against protein toxicity, proposing
Hsp90 inhibition as a pharmacological intervention to
therapeutically increase expression of molecular chaper-
one proteins to treat neurodegenerative diseases where
aggregation is central to the pathogenesis (Fig. (1)). On
the other hand, Hsp90 inhibition may ameliorate protein
hyperphosphorylation and subsequent aggregation by
reduction of aberrant neuronal protein activity (Fig. (3)).
The usefulness of Hsp90 inhibitors as clinical agents in
neurodegenerative diseases will depend on whether their
effects occur at concentrations of drug that are not toxic
and on whether the drugs can be administered chroni-
cally in such a fashion so as to safely achieve these con-
centrations in the brain. While studies in several cellular
models show promise for this class of compounds in
treating a large spectrum of neurodegenerative diseases,
these studies need to be furthered in animal models, with
the goal of testing both Hsp90 inhibitors efficacy in
improving neuro-pathology and their safety under long-
term administration schedules. While several of the stud-
ies have used GM and its derivatives, these agents have
several liabilities that limit their future clinical use [50].
Development for cancers of Hsp90 inhibitors of scaffolds
distinct from that of GM is currently reaching an explo-
sive phase, where several agents are in clinical evaluation,
with many others following behind [50]. It is likely that
the Hsp90 inhibitor classes with best safety profiles will
also move into the neurodegenerative space. It now
remains the goal of medicinal chemistry to deliver CNS-
permeable Hsp90 inhibitors with a good therapeutic
index to fulfill the promise of these agents in the treat-
ment of neurodegenerative diseases.
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